Zte Corporation

Shanghai Hengrui Pharmaceutical Co., Ltd.

Jiangsu Hengrui Medicine Company Ltd.

Novartis Ag

Philips Lighting Holding B.v.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Huawei Technologies Co., Limited

Bristol-myers Squibb Compnay

Xi'an Zhongxing New Software Co., Ltd.

Huawei Device (dongguan) Co., Ltd.

Agora Lab, Inc.

Jinagsu Hengrui Medicine Co., Ltd

Shanghai Escugen Biotechnology Co., Ltd.

Geberit International Ag

Feng He

Weikang Tao

Fanglong Yang

Yin Gao

Zhuoliang Chen

Lifeng Han

Xin Wang

Yuan Mi

Fan Yang

Shuang Liang

Lei Jiang

Yue Ping Li

Gang Liu

Lei Liu

Fei Li

Stefan Peukert

Ling L Zhang

Jianmin Fang

Qiyue Hu

Chao Chen

Linghang Zhuang

Piyasena Hewawasam

Wei He

Piaoyang Sun

Yang Chen

Thomas W Hudyma

Minsheng Zhang

Robert G Gentles

Min Ding

Xiaofan Zheng

Bharat Lagu

Scott W Martin

Dong Liu

Guobao Zhang

Gang Chen

He Huang

Zijiang Ma

Yada Huang

Bin Wang

Jianxun Ai

Dapeng Li

Bin Wu

Takuya Matsumoto

Jian Liu

Wei Zhang

Peter Hubertus Franciscus Deurenberg

Tao Liu

Qin Li

Lawrence Blas Perez

Zhi Quan Chen

Mark G Palermo

Miao Dai

Christopher Sean Straub

Leigh Zawel

Mark G Charest

Run-Ming David Wang

Sushil Kumar Sharma

Yao-Chang Xu

Fang Liang

Jun Feng

Qiyun Shao

Ji Yue Zhang

Guoliang Xun

Rumin Zhang

Christine Hiu-Tung Chen

Mark Gabriel Palermo

Naeem Yusuff

Zhengtian Yu

Yaping Wang

Huangshu Lei

Jingjing Yan

Xingnian Fu

Karen Marie Miller-Moslin

Haibing Guo

Carl P Bergstrom

Hongping Yu

Fengqi Zhang

Yinfa Yan

Haibing Deng

Xiaodong Li

Xing Fan

Mingxun He

Xiao Wu

Zhenxing Du

Chao Xu

Yun Deng

Rajesh Karki

Chengyan Feng

Heping Wu

Xiaomin Zhang

Jin Xi

Junfeng Zhou

Jun Yao

Shengming Wang

Lin Wang

Qiangang Zheng

Long Han

Ji Yue (Jeff) Zhang

Guangyuan Shen

Qing Zhou

Disclosed are fused imidazole derivatives, preparation methods therefor and medical uses thereof. Specifically, the present disclosure relates to a fused imidazole derivative as shown in general formula (IM), a preparation method therefor, a pharmaceutical composition containing the derivative, and the use of same as a therapeutic agent, in particular the use thereof as a GLP-1 receptor agonist, and the use thereof in the preparation of drugs for the treatment and/or prevention of diabetes.

Fused imidazole derivative, preparation method therefor, and medical use thereof

The present application relates to an anti-CD47 single-domain antibody and a use thereof, and a method for preparing the antibody. The single-domain antibody comprises a CDR selected from the following CDRs: (1) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO:3; or (2) CDR1, CDR2, and CDR3 shown by SEQ ID NO: 6, SEQ ID NO: 7, and SEQ ID NO: 8.

Human CD47-targeting single-domain antibody and use thereof

A fused pyridine ring derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and a use thereof as a therapeutic agent, particularly, in preparation of drugs for preventing and/or treating HIV infection.

Fused pyridine ring derivative, preparation method therefor, and pharmaceutical use thereof

The present disclosure relates to a tricyclic tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, the present disclosure relates to a tricyclic tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutical composition comprising said derivative, a use thereof as an estrogen receptor modulator, and a use thereof in preparing a drug for treating estrogen receptor-mediated or dependent diseases or disorders. The substituents in general formula (I) are the same as those defined in the description.

Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine

An indazole derivative, a preparation method therefor, and a pharmaceutical application thereof. In particular, the present invention relates to an indazole derivative represented by general formula (I), a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use of the derivative as an estrogen receptor modulator in the prevention and/or treatment of an estrogen receptor mediated or dependent disease or condition, the disease being particularly preferably breast cancer. The definition of each substituent in the general formula (I) is the same as that in the description.

Indazole derivative, preparation method therefor, and pharmaceutical application thereof

The present disclosure relates to a crystal form of a pyridopyrimidine derivative and a preparation method thereof, and specifically relates to the crystal form of the compound of formula (I) and a preparation method thereof. The new crystal form has good physical and chemical properties, thereby facilitating clinical treatments.

Crystal form of pyridopyrimidine derivative and preparation method thereof

The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (RORγ) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of RORγ-mediated diseases or disorders.

Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (RORγ) and pharmaceutical use thereof

Disclosed are a pyridopyrimidine derivative as shown in general formula (I), a preparation method therefor and a pharmaceutical composition containing the derivative, and the use thereof as a therapeutic agent, particularly as a TLR8 agonist, wherein each substituent of general formula (I) is the same as those defined in the description.

Pyridopyrimidine derivative, preparation method therefor and medical use thereof

This application provides example image display methods, media, and electronic devices. One example method includes detecting, by an electronic device that has a camera and a display, an operation of opening experience data by a user, where the experience data is stored in the electronic device and includes video data, and the video data includes multiple frames of images. A first interface is displayed in response to the operation, where the first interface includes a first image. Pose change information is determined within a preset duration, where the pose change information includes location movement information of the electronic device and pose change information of the camera. A second image including digital signage or a 3D virtual object is displayed based on pose data during collection of the first image and based on the pose change information, where the multiple frames of images include the second image.

Image display method and electronic device

A data sharing method and a device are provided. A first image is obtained by integrating a first 3D identifier and a second 3D identifier of a digital world into an image of a real world captured by a camera and performing AR rendering, the first 3D identifier is used to identify at least a building, a plant, or a mountain scenery in the real world, and the second 3D identifier is used to identify a first user in the first image. The first device displays one or a plurality of virtual objects in response to a second operation. In response to a sliding operation of which a start point of a sliding track is a first virtual object and an end point is an image of the first user, a server is requested to transmit the first virtual object to a second device.

Data sharing method and device

This application discloses a new class of fused tricyclic heterocycles of formula (I), preparation methods thereof, pharmaceutical compositions comprising these compounds, and pharmaceutically acceptable salts, solvates, or prodrugs thereof, and their uses for the treatment of diseases in which modulation of STING is beneficial, for example, cancers, pre-cancerous disorders, and viral infections. 

Fused tricyclic heterocycle compounds and therapeutic uses thereof

The present invention relates to benzimidazole derivatives of formula (I) as inhibitors of retinoid-related orphan receptor gamma (ROR&#x3b3;) protein, pharmaceutical compositions containing the compounds, preparation methods thereof, and the use of the compounds as therapeutic agents for the treatment of ROR&#x3b3;-mediated diseases or disorders. 

Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ROR&#x3b3;) and pharmaceutical uses thereof

Disclosed is a method for preparing a benzofuran derivative. In particular, provided is a method for preparing a benzofuran derivative, wherein according to the method provided, reaction steps required to synthesize the benzofuran substance in the prior art can be effectively shortened.

Method for preparing benzofuran derivative

Growing community of inventors

Shanghai, China

Feng He